Figure 2

Tumor response after NKTR-102 discontinuation. A: Partial response at the 12th cycle of pegylated irinotecan NKTR-102. B: Abdominal computed tomography scan four months after the last course of pegylated irinotecan NKTR-102, showing additional response.